meta
|
evidence
oncology
Living systematic review and meta-analysis
metastatic/advanced RCC (mRCC) - (neo)adjuvant(NA)
3
immune chekpoint inhibitors
anti-PD-(L)1
atezolizumab based treatment
atezolizumab alone
nivolumab based treatment
nivolumab alone
pembrolizumab based treatment
pembrolizumab alone
versus all
vs immune chekpoint inhibitors
vs Immune checkpoint association
vs nivolumab plus ipilimumab
vs non active control
vs no additional treatment
vs placebo
study list
mapping
overview
meta-analysis
forest plot
NMA
excluded
graph
EGM
comparisons
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
nivolumab alone
title
nivolumab plus ipilimumab
title
CheckMate 914, 2017 NCT03138512 metastatic/advanced RCC (mRCC) - (neo)adjuvant(NA) -9/-9
Pathology:
metastatic/advanced RCC (mRCC) - (neo)adjuvant(NA);
metastatic/advanced RCC (mRCC) - (neo)adjuvant(NA)
CheckMate 914, 2017
nivolumab alone
1
T1
nivolumab plus ipilimumab
0
T0